Poster discussion
TB treatment: new drugs and drug resistance
Minimal inhibitory concentrations (MICs) of mefloquine: in vitro activity against MDR- and nonMDR-Tb strains
D. Krieger(Berlin, Germany)
COI
1
Efficacy of moxifloxacin in TB resistant to isoniazid
M. Kuzhko(Kyiv, Ukraine)
COI
2
Neuroleptic drugs as potential adjuvants in the treatment of MDR-TB: Minimal inhibitory concentrations (MICs) of different phenothiazines against M. tuberculosis
S. Vesenbeckh(Zürich, Switzerland)
COI
3
Clofazimine for the treatment of multidrug-resistant tuberculosis: Prospective, multicenter, randomized controlled study in China
S. Tang(Shanghai, China)
COI
4
Minimum inhibitory concentrations (MIC) determination of TB drugs and broad-spectrum antibiotics in M.tuberculosis with M/X/TDR
S. Popov(Moscow, Russian Federation)
COI
5
HIV co-infection excludes many drug-resistant tuberculosis patients from clinical trials with novel antituberculosis drugs
F. von Groote-Bidlingmaier(Cape Town, South Africa)
COI
6
Rifampicin-resistant TB on Gene Xpert: What is the best empiric combination treatment while awaiting cultures?
L. Pinto(Mumbai, India)
COI
7
Evaluation of failures treated with linezolid-containing regimen for extensively drug-resistant tuberculosis (XDR-TB)
M. Lee(Seoul, Republic of Korea)
COI
8
Prospects for early implementation of ambulatory treatment in XDR TB patients by optimizing the administration of linezolid at the intensive phase of chemotherapy
S. Cherenko(Kyiv, Ukraine)
COI
9
Administration of linezolid, bedaquiline and imipenem in treatment of patients with extensively drug-resistant tuberculosis
D. Esmedlyaeva(St. Petersburg, Russian Federation)
COI
10
Impact of pre-treatment duration by first line drugs on treatment outcomes of patients with MDR-TB
Y. Batyrshina(Novosibirsk, Russian Federation)
COI
11
Efficacy of treatment of MDR/XDR TB patients with diabetes mellitus
I. Vasilyeva Anatolievna(Moscow, Russian Federation)
COI
12
Cost-effectiveness of treating MDR-TB by adding delamanid to background regimens in Germany
R. Diel(Großhansdorf, Germany)
COI
13
Electronic nose as a surrogate marker of response to treatment of pulmonary tuberculosis (ELNOSUR study)
R. Coronel Teixeira(Asunción, Paraguay)
COI
14
Evaluation of optimal regimens for treatment of rifampicin resistant-tuberculosis: Multicenter, randomized controlled study in China
S. Tang(Shanghai, China)
COI
15
Should MRI be used to determine the duration of treatment in spinal tuberculosis?
E. Mcghee(Hertfordshire, United Kingdom)
COI
16
An incidence of the ethambutol-induced optic neuropathy and the usefulness of periodic visual acuity test – A questionnaire survey in Japan
M. Matsumoto(Miki, Japan)
COI
17
Influence of mycobacterium tuberculosis strains on recurrence of tuberculosis in Hanoi, Vietnam
N. Hang(Hanoi, Vietnam)
COI
18
. . .
